Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
ATLANTA, Georgia — Patients with chronic obstructive pulmonary disease (COPD) experience few adverse events and discontinuations when treated with an ipratropium plus albuterol inhalation spray (CVT-R ...
COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced a voluntary recall of over 350,000 Combivent Respimat (ipratropium ...
COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced that Combivent Respimat (ipratropium bromide and albuterol) inhalation ...
RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday. BI Pharmaceuticals announced the launch of ...
Boehringer makes significant investment to improve the affordability of and access to its full range of inhaler products for COPD and asthmaExpansive program builds on the company's century-long ...
March 7 (Reuters) - Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma at $35 per month starting June 1, the German drugmaker ...
Connecticut-based Boehringer Ingelheim Pharmaceuticals Inc. has been hit with a prospective class action lawsuit that alleges its Combivent asthma inhaler provides far less than the number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results